BioCytics and CBOI Publish Novel Solution for Immune Cell Therapy Manufactured at the Point-of-Care

Transfusion – 10/9/26

The team at BioCytics and Carolina BioOncology Institute (CBOI) collaborated to produce an article recently published in a special supplemental edition of Transfusion, the official journal of the American Association of Blood and BioTherapeutics. The Transfusion special edition is called “Evolving Biotherapies: Stakeholders, Solutions, and the Science of Tomorrow”. BioCytics-CBOI’s manuscript is titled “Enabling community-based autologous adaptive immune cellular therapy manufactured at the point of care: A narrative review of global regulatory frameworks, affordability, and implementation strategy of a novel integrated facility and digital platform in the United States”.

Strategic Collaboration to Develop Advanced Cancer Screening Platforms and Companion Diagnostics

BioCytics and LIDE Biotech Initiate Pilot Project to Develop PDX Cancer Models – 8/13/26

BioCytics, Inc., and LIDE Biotech are proud to announce the formation of a strategic alliance to develop advanced screening platforms and companion diagnostics for immune-based cancer cell therapies. This collaboration combines BioCytics’ specialized cell manufacturing capabilities with LIDE’s unique, patient-derived xenograft technologies (PDX, miniPDX®, and IO-based PDX models) to streamline the development of immuno-oncology (IO) treatments.

Unlocking the Dark Genome of Cancer: A Landmark Collaboration Between BioCytics and UNC Charlotte

Collaboration with UNC Charlotte – 7/20/26

BioCytics and UNC Charlotte, along with Carolina BioOncology Institute, are embarking on a new project to study as-yet unidentified sequences in the human genome that might be responsible for cancer cell growth and treatment response.  BioCytics’ Chief Scientific Officer, Dr. Renaud Warin, and UNC Charlotte Associate Professor, Dr. Richard White III, are embarking on a collaboration that involves studying the “dark genome” of cancer cells.  The dark genome is the portion of the genome (approximately 98%) that does not directly code for a protein.  The goal of this project is to identify viral and immune sequences involved in the progression of cancer and immune response to cancer.

Dr. John Powderly Heads Discussion Group at openEHR International and HL7’s 2026 “Converge and Collaborate” Meeting

Converge and Collaborate – 5/14/26

On May 12^th and 13^th in Dublin, Ireland, openEHR International and HL7 (Health Level Seven) hosted their second annual in-person meeting called “Converge and Collaborate”.  With an overall focus on cancer treatment support, this meeting also had the broader aim of increasing the collaborative agenda at the heart of these two organizations, which is improving interoperability for healthcare data exchange.

Dr. John Powderly, President and CEO of both Carolina BioOncology Institute and BioCytics, led a working group discussion around the idea of the convergence of Clinical Research and Informatics. He was also able to explain to an interested audience about the openEHR Affiliate Program, which allows any country or specific field in the medical/health sciences to form a group as part of openEHR International.  These Affiliate Groups help with digital transformation initiatives in all areas where clinical data standards are used or needed.